Treatment resistant schizophrenia – less urban myth than rural reality

Fullscreen

Treatment resistant schizophrenia (TRS) is an on-going challenge in psychiatry. Too often available pharmacological therapies fail, either at the outset or during treatment, to completely control the debilitating symptoms experienced by patients. Clearly, a different approach to TRS is needed.

Non- or partial response to D2 antagonists = TRS

What is TRS? John Kane, New York, USA, explained that international treatment guidelines broadly agree that TRS is present when there is no significant improvement in target symptoms after treatment with at least two different antipsychotics given at adequate dose and duration. This definition assumes patients are fully compliant.

That there are over 21 million people with schizophrenia worldwide, 30% of whom fail to respond - and a further 30% of whom only partially respond - to the over 60 different therapies available, attests to the burden of disease.

Of over 21 million people with schizophrenia worldwide, 30% fail to respond - and a further 30% only partially respond to the different therapies available.

TRRIP consensus guidelines facilitate consistent research

Earlier identification and prompt pharmacological intervention can potentially change the course of the disease and improve outcomes. The Treatment Response and Resistance in Psychosis (TRRIP) working group has developed consensus guidelines on diagnosis and terminology that help facilitate more timely recognition of and consistent research into TRS.

What has become increasingly apparent is that there is clinical and pathophysiological heterogeneity within TRS; some patients never respond to treatment while in others resistance to treatment develops over time. Clearly this complicates matters and suggests there are different pathologies and, therefore, clinical pathways towards resistance.

Clinical and pathophysiological heterogeneity within TRS

However, potential clinical predictors of TRS are becoming apparent. These include use of antipsychotic combination therapy, recurrent relapses (where with each relapse the patient becomes less responsive to treatment and experience a worsening of clinical outcomes) and more that 30 days in psychiatric hospital in the year before diagnosis.

TRS – less urban myth than rural reality

Interestingly, the risk factors for schizophrenia that respond to D2 antagonists, such as urban living and male gender, are different to those for TRS. Typically, TRS patients are younger, live rurally, attain a primary educational level, have co-morbid personality disorders and/or a paranoid subtype and have previously received antipsychotics and antidepressants.

Risk factors factors for schizophrenia that responds to D2 antagonists, such as urban living and male gender, are different to those for TRS

Novel neurobiologies and hypotheses

If available antipsychotic agents aren’t working in TRS, this suggests that the neurobiology underlying the condition are novel or in some way different to those currently accepted, Oliver Howes, London, UK, explained.

Normodopaminergic profiles correlates with TRS non-response?

One hypothesis supported by imaging data suggests that patients who respond to D2 antagonists have a hyperdopaminergic profile - characterized by elevated striatal dopamine synthesis and release capacity and greater density of dopaminergic synapses. This contrasts with patients who have a normodopaminergic profile that leaves them unable to respond to dopamine D2 blocking drugs and who likely are TRS non-responders.

Patients with normodopaminergic profiles cannot respond to D2 antagonists and are likely TRS non-responders.

Dopamine supersensitivity psychosis and treatment resistance

A second hypothesis for which supporting animal and human data are available suggests that dopamine supersensivity psychosis (DSP) develops with long-term use of antipsychotics. Prolonged blockade of the D2 receptors may induce upregulation or alter their affinities thereby creating receptor supersensitivity. Thus, giving increased doses of D2 antagonists over time, as happens in patients who initially respond to antipsychotics but in whom therapeutic benefit diminishes, will eventually lead to treatment resistance.

Dopamine supersensivity psychosis (DSP) likely develops in TRS patients who become treatment- resistant.

Many and varied alternative hypotheses

Several other hypotheses have been proposed including abnormalities in other systems, including glutamate, neuroinflammation, brain connectivity and neurodegeneration. In particular, elevated glutamate levels and IL-6 have been detected in patients with TRS

Genetic polymorphisms and substance abuse may also be involved in TRS.

In all likelihood there are probably several pathways to TRS and they are not mutually exclusive. After all, as Dr Howes stated, if a patient is normodopaminergic, something else must be causing their TRS.

Suboptimal approved option in TRS despite different MoA

Currently, only a single drug is approved for use in TRS albeit as third line treatment. However, as James McCabe, London, UK, explained, its use is often delayed due to clinicians’ reluctance to use it due to the need for regular blood tests and concerns over its safety and tolerability. Indeed, some go so far as to use non-evidence-based treatments in preference, including switching, combination therapies and increased dosages.

One feature of the approved drug is that, unlike currently used antipsychotics, its mode of action is distinct. However, if this approved option is suboptimal, it is clear there is great need for others that are not. In the meantime, clinicians should be encouraged to consider this agent more often – even as second line therapy in patients who have definitive TRS – and definitely sooner than is currently happening.

Unlike currently used antipsychotics, the approved therapy’s mode of action is distinct.

The report is from an ECNP satellite symposium sponsored by Lundbeck.

Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.

Symposium references
  1. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004 Feb;161(2 Suppl):1-56.
  2. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia - a short version for primary care. Int J Psychiatry Clin Pract. 2017 Jun;21(2):82-90.
  3. Iasevoli F, Giordano S, Balletta R, Latte G, Formato MV, Prinzivalli E et al. Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones. Prog Neuropsychopharmacol Biol Psychiatry. 2016 Feb 4;65:34-48.
  4. Kennedy JL, Altar CA, Taylor DL, Degtiar I, Hornberger JC. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol. 2014 Mar;29(2):63-76.
  5. Howes OD1, McCutcheon R1, Agid O1, de Bartolomeis A1, van Beveren NJ1, Birnbaum ML et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry. 2017 Mar 1;174(3):216-229.
  6. Howes OD, Kapur S. A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic). Br J Psychiatry. 2014 Jul;205(1):1-3.
  7. Suzuki T, Kanahara N, Yamanaka H, Takase M, Kimura H, Watanabe H, Iyo M. Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia. Psychiatry Res. 2015 Jun 30;227(2-3):278-82.
  8. Šagud M. Treatment-resistant schizophrenia: challenges and implications for clinical practice. Psychiatr Danub. 2015 Sep;27(3):319-26.
  9. Stroup TS, Gerhard T, Crystal S, Huang C, Olfson M. Geographic and clinical variation in clozapine use in the United States. Psychiatr Serv. 2014 Feb 1;65(2):186-92.
  10. Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry. 2012 Dec;201(6):481-5.
  11. Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med. 1997 Sep 18;337(12):809-15.
  12. Thompson JV, Clark JM, Legge SE, Kadra G, Downs J, Walters JT, et al. Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-resistant schizophrenic disorders. J Psychopharmacol. 2016 May;30(5):436-43.
  13. Gillespie AL, Samanaite R, Mill J, Egerton A, MacCabe JH. Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review. BMC Psychiatry. 2017 Jan 13;17(1):12.
Country selection
We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil
You are leaving Progress in Mind